Ovarian Cancer
Tango Therapeutics to Go Public on Nasdaq Through SPAC
The combined company is expected to receive $353 million in gross proceeds, which will help advance several of Tango's precision oncology drug candidates.
NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund
While more data are collected, the CDF can provide the regimen to advanced, HRD-positive ovarian cancer patients after first-line platinum chemo and bevacizumab.
The firm highlighted a new study exploring immune-related gene expression in ovarian cancer and gave an update on its lead diagnostic candidate for head and neck tumors.
The firm's BRAF inhibitor, PLX8394, targets cancers with non-V600 BRAF mutations that see little benefit from BRAF inhibitors currently on the market.
Molecular Health Inks Agreement for Precision Medicine Tools With Falco Biosystems
The tools are part of Molecular Health's MH Guide platform, which analyzes sequencing data to identify and report on disease-related gene variants.